Table 5 Concentrations of markers of bone turnover
Visit | Iron group (n) | Median (IQR) | p-value | p- value (within group analysis) |
|---|---|---|---|---|
ALP | ||||
Baseline | FDI (14) | 96.0 (79.0–153.0) [iU]/L | 0.667 | |
FCM (12) | 107.0 (77.8–129.8) [iU]/L | |||
1–2 days post 1st infusion | FDI (14) | 104.0 (82.5–159.5) [iU]/L | 0.893 | |
FCM (11) | 110.0 (82.0–150.0) [iU]/L | |||
2 weeks | FDI (13) | 110.0 (74.0–136.5) [iU]/L | 0.832 | |
FCM (10) | 112.5 (90.5–139.0) [iU]/L | |||
1 month (2nd infusion) | FDI (12) | 99.5 (78.2–131.5) [iU]/L | 0.525 | |
FCM (11) | 112.0 (90.0–140.0) [iU]/L | |||
1–2 days post 2nd infusion | FDI (9) | 110.0 (78.0–136.0) [iU]/L | 0.604 | |
FCM (10) | 123.5 (87.5–152.8) [iU]/L | |||
2 months | FDI (13) | 124.0 (90.0–145.0) [iU]/L | 0.879 | Within FDI: 0.427 |
FCM (10) | 118.0 (90.7–168.0) [iU]/L | Within FCM: 0.016 | ||
BALP | ||||
Baseline | FDI (14) | 21.3 (16.6–26.8) [U]/L | 0.462 | |
FCM (12) | 18.7 (14.1–27.5) [U]/L | |||
1–2 days post 1st infusion | FDI (14) | 18.6 (15.7–26.7) [U]/L | 0.767 | |
FCM (11) | 17.0 (12.6–31.8) [U]/L | |||
2 weeks | FDI (13) | 20.4 (16.6–23.8) [U]/L | 0.738 | |
FCM (10) | 17.9 (16.7–24.1) [U]/L | |||
1 month (2nd infusion) | FDI (12) | 20.6 (15.0–24.2) [U]/L | 0.740 | |
FCM (11) | 18.5 (17.1–35.4) [U]/L | |||
1–2 days post 2nd infusion | FDI (9) | 20.9 (15.7–27.8) [U]/L | 0.905 | |
FCM (10) | 19.9 (16.7–35.1) [U]/L | |||
2 months | FDI (12) | 19.8 (17.6–25.0) [U]/L | 0.203 | Within FDI: 0.883 |
FCM (10) | 22.9 (19.9–28.8) [U]/L | Within FCM < 0.001 | ||
CTx | ||||
Baseline | FDI (14) | 0.84 (0.56–1.01) µg/ml | 0.560 | |
FCM (12) | 0.98 (0.49–1.18) µg/ml | |||
1–2 days post 1st infusion | FDI (14) | 0.81 (0.51–0.97 µg/ml | 0.767 | |
FCM (11) | 0.73 (0.44–1.19) µg/ml | |||
2 weeks | FDI (13) | 0.77 (0.55–0.87) µg/ml | 0.927 | |
FCM (10) | 0.69 (0.51–1.05) µg/ml | |||
1 month (2nd infusion) | FDI (12) | 0.74 (0.49–.105) µg/ml | 0.316 | |
FCM (11) | 0.99 (0.58–1.32) µg/ml | |||
1–2 days post 2nd infusion | FDI (9) | 0.71 (0.46–0.84) µg/ml | 0.211 | |
FCM (10) | 0.88 (0.50–1.17) µg/ml | |||
2 months | FDI (12) | 0.84 (0.50–1.13) µg/ml | 0.582 | Within FDI: 0.905 |
FCM (10) | 0.94 (0.60–1.48) µg/ml | Within FCM: 0.006 | ||
P1NP | ||||
Baseline | FDI (14) | 112.0 (70.3–178.8) µg/L | 0.820 | |
FCM (12) | 103.0 (63.0–166.3) µg/L | |||
1–2 days post 1st infusion | FDI (14) | 108.0 (63.6–156.8) µg/L | 0.767 | |
FCM (11) | 89.0 (55.0–164.0) µg/L | |||
2 weeks | FDI (13) | 107.0 (64.0–126.0) µg/L | 0.784 | |
FCM (10) | 77.5 (56.3–158.8) µg/L | |||
1 month (2nd infusion) | FDI (12) | 98.0 (63.0–118.0) µg/L | 0.748 | |
FCM (11) | 85.0 (56.0–166.0) µg/L | |||
1–2 days post 2nd infusion | FDI (9) | 80.0 (50.5–116.0) µg/L | 0.780 | |
FCM (10) | 71.0 (56.7–174.5) µg/L | |||
2 months | FDI (12) | 97.0 (50.8–156.5) µg/L | 0.722 | Within FDI: 0.439 |
FCM (10) | 104.5 (55.3–181.8) µg/L | Within FCM: 0.459 | ||